Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors

NCT02082626 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT02082626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02082626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors
Lead sponsor
University of Oklahoma
Phase
Phase 1
Overall status
Terminated
Start date
February 1, 2014
Completion date
June 30, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, pediatric cancer, solid tumors